ArticleGenes & cancer2017
SIRT6 histone deacetylase functions as a potential oncogene in human melanoma.
Article in Genes & cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 54 citations in OpenAlex.
- Beyond deacetylation: crosstalk mechanisms and context-dependent regulation of sirtuin non-classical enzymatic functions in disease.Molecular medicine (Cambridge, Mass.) · 2026Review
- Mechanisms of the Antiproliferative Effects of SIRT6 Inhibition in Melanoma: A Multi-Omics Analysis.Cancers · 2026Article
- SIRT6 promotes a mesenchymal, invasive phenotype in melanoma.Journal of dermato-oncology · 2026Article
- Metabolic Reprogramming in Melanoma: An Epigenetic Point of View.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A review shows that ATG10 has been identified as a potential prognostic marker and therapeutic target for cancer patients based on real-world studies.Frontiers in oncology · 2025Review
- Melanoma Metabolism: Molecular Mechanisms and Therapeutic Implications in Cutaneous Oncology.Cancer medicine · 2024Review
- Discovery of a potent and highly selective inhibitor of SIRT6 against pancreatic cancer metastasisActa pharmaceutica Sinica. B · 2024Article
- Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.Cancers · 2024Review
- Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective.Cell death discovery · 2023Review
- PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.The Prostate · 2022Article
- Role of sirtuins in esophageal cancer: Current status and future prospects.World journal of gastrointestinal oncology · 2022Review
- SIRT6 Widely Regulates Aging, Immunity, and Cancer.Frontiers in oncology · 2022Review
- Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma.Journal of personalized medicine · 2021Review
- The deacylase SIRT5 supports melanoma viability by influencing chromatin dynamics.The Journal of clinical investigation · 2021Article
- Screening of SIRT6 inhibitors and activators: A novel activator has an impact on breast cancer cells.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- The Two-Faced Role of SIRT6 in Cancer.Cancers · 2021Review
- Emerging roles of SIRT6 in human diseases and its modulators.Medicinal research reviews · 2021Review
- Review
- SIRT6 inhibits metastasis by suppressing SNAIL expression in nasopharyngeal carcinoma cells.International journal of clinical and experimental pathology · 2021Article
- Sirtuin Modulators in Cellular and Animal Models of Human Diseases.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Melanoma is an aggressive skin cancer that can rapidly metastasize to become fatal, if not diagnosed early. Despite recent therapeutic advances, management of melanoma remains difficult. Therefore, novel molecular targets and strategies are required to manage this neoplasm. This study was undertaken to determine the role of the sirtuin SIRT6 in melanoma. Employing a panel of human melanoma cells and normal human melanocytes, we found significant SIRT6 mRNA and protein upregulation in melanoma cells. Further, using a tissue microarray coupled with quantitative Vectra analysis, we demonstrated significant SIRT6 overexpression in human melanoma tissues. Lentiviral short hairpin RNA-mediated knockdown of SIRT6 in A375 and Hs 294T human melanoma cells significantly decreased cell growth, viability, and colony formation, induced G1-phase arrest and increased senescence-associated beta-galactosidase staining. As autophagy is important in melanoma and is associated with SIRT6, we used a qPCR array to study SIRT6 knockdown in A375 cells. We found significant modulation in several genes and/or proteins (decreases in AKT1, ATG12, ATG3, ATG7, BAK1, BCL2L1, CLN3, CTSB, CTSS, DRAM2, HSP90AA1, IRGM, NPC1, SQSTM1, TNF, and BECN1; increases in GAA, ATG10). Our data suggests that increased SIRT6 expression may contribute to melanoma development and/or progression, potentially via senescence-and autophagy-related pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.